Trial Profile
Prospective randomised study of doxorubicin [DC Bead] in the treatment of hepatocellular carcinoma by drug-eluting bead embolisation (PRECISION V)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms PRECISION V
- Sponsors Biocompatibles International
- 14 Jun 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
- 04 Jun 2010 Tolerability results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
- 12 Oct 2009 Results have been presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.